As of today, three afucosylated mAbs have been marketed for the treatment of human cancers: Obinutuzumab, a CD20-directed afucosylated antibody approved for the treatment of chronic lymphocytic leukemia (CLL); Poteligeo (mogamulizumab), a CCR4-targeting afucosylated mAb, approved for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS); and Fasenra (benralizumab), an afucosylated IL-5Rα targeting mAb for the treatment of patients with severe eosinophilic asthma. This evidence concerns the gene CCR4 and mycosis fungoides.